1,152 material Form 8-K filings that 918 companies we cover made with the SEC in October 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Agilent Technologies appointed Adam S. Elinoff, currently vice president of investor relations and treasurer at Amgen, as senior vice president and chief financial officer effective November 17, 2025, replacing interim CFO Rodney Gonsalves, who remains corporate controller and principal accounting officer. The filing discloses a compensation package including a $700,000 base salary, equity awards, and an $800,000 one-time cash bonus, which matters to shareholders as a change in the leader of the company's finance function.
Adam S. Elinoff, age 48, becomes CFO effective November 17, 2025, succeeding Rodney Gonsalves, who has been interim CFO since July 31, 2025.
Elinoff's base salary is $700,000, with bonus eligibility of 80% of base salary.
Equity awards include $1,100,000 in fiscal 2025 RSUs, $1,650,000 in performance-based RSUs for fiscal 2026 to 2028, and sign-on grants of $560,000 in RSUs and $840,000 in performance-based RSUs.
A one-time $800,000 cash bonus is subject to repayment if he leaves within twelve months.
Dexcom appointed Stanford Chair of Medicine Dr. Euan Ashley as a director effective October 24, 2025, and he joined the Nominating and Governance and Technology Committees. The Board also confirmed that the board will increase to eleven directors effective January 1, 2026, with Jacob S. Leach's appointment as a director also taking effect that day, provided he continues to serve the company.
Dr. Euan Ashley appointed director effective October 24, 2025, with a term running to the 2026 annual meeting
Initial equity grant of restricted stock units with a fair value of $500,000, vesting annually over three years
Annual director equity grant expected at the 2026 annual meeting with a fair value of $345,000
Kyle Malady steps down from the Nominating and Governance Committee but remains Technology Committee chair
Amkor reported third-quarter 2025 net sales of $1.99 billion, up from $1.86 billion a year earlier, with net income of $127 million and diluted EPS of $0.51 versus $0.49 in the prior-year quarter. The company also said CEO Giel Rutten will retire on December 31, 2025, and that Chief Operating Officer Kevin Engel will succeed him, with Rutten remaining on the board and Engel joining it. Fourth-quarter guidance calls for net sales of $1.775 billion to $1.875 billion and diluted EPS of $0.38 to $0.48.
Q3 2025 net sales $1.99 billion, up 31% from Q2 2025 and up from $1.86 billion in Q3 2024; net income $127 million, diluted EPS $0.51
Q4 2025 guidance: net sales of $1.775 billion to $1.875 billion; net income of $95 million to $120 million, or $0.38 to $0.48 per diluted share
Kevin Engel to become President and CEO effective January 1, 2026, with a starting base salary of $900,000 and a target bonus of 125% of salary
Rutten will advise the company through March 31, 2026, then join the board as a non-employee director beginning April 1, 2026
CareTrust REIT, Inc. increased its board from five to six directors and appointed Gregory K. Stapley, its CEO from 2014 to 2022, effective January 1, 2026. The board also adopted amended and restated bylaws effective October 21, 2025, updating director nomination rules and adding a Chief Investment Officer office. Mr. Stapley is the brother-in-law of current CEO David Sedgwick, which the filing discloses.
Board expanded from five to six directors; Mr. Stapley's appointment is effective January 1, 2026
Director pay includes an $85,000 annual cash retainer and a restricted stock award with a $145,000 grant date value
Bylaws amended October 21, 2025 to add universal proxy requirements and tighter advance notice rules for director nominations
Mr. Stapley is the brother-in-law of President and CEO David Sedgwick
Toast, Inc. appointed Anu Bharadwaj, President of Atlassian, to its Board of Directors effective October 24, 2025, as a Class I director serving until the 2028 annual meeting. The filing describes a $400,000 initial restricted stock unit grant under the company's non-employee director program, which is a routine board addition with no financial results or guidance included.
Board appointment effective October 24, 2025; term runs until the 2028 annual meeting of stockholders
Initial restricted stock unit grant valued at $400,000, vesting in equal annual installments over three years
Ms. Bharadwaj is President of Atlassian Corporation, having served as COO from August 2021 to February 2023
Press release announcing the appointment issued October 27, 2025 and furnished as Exhibit 99.1
Organon CEO Kevin Ali resigned on October 26, 2025, as CEO and board member in connection with an Audit Committee investigation into wholesaler sales practices for Nexplanon. Joseph Morrissey was named interim CEO, and Chair Carrie Cox became interim Executive Chair. The company says the findings do not require a restatement, but it has concluded that its prior internal control assessment and auditor's opinion for 2024 should no longer be relied upon.
Kevin Ali resigned as CEO and director on October 26, 2025, and will not receive severance or equity-related retirement benefits.
Joseph Morrissey, Executive Vice President and Head of Manufacturing & Supply, was appointed interim CEO with a $1 million salary, a 100% bonus target, a $4 million long-term incentive target next year, and a one-time $1 million RSU grant.
Investigation found Nexplanon wholesaler purchases in several 2022, 2024 and 2025 periods, which were under 1% of annual consolidated revenue and helped meet guidance or external revenue expectations.
The company expects to file an amended 2024 Form 10-K and amended Forms 10-Q for the first two 2025 quarters, and a third quarter 2025 10-Q by the SEC deadline.
Dime Community Bancshares said Conrad Gunther, its commercial banking executive since 2017, will retire at the end of 2025, with Thomas X. Geisel taking over his responsibilities as Chief Commercial Officer. Avi Reddy, the current Chief Financial Officer, will also take on the additional title of Chief Operating Officer, and the company described these moves as part of a senior executive succession plan.
Conrad Gunther to retire at the end of 2025 after a career the company says spans over 50 years
Thomas X. Geisel assumes Gunther's responsibilities and is appointed Chief Commercial Officer; the transition occurs over the next couple of months
Avinash (Avi) Reddy keeps his CFO role and adds the title of Chief Operating Officer, in recognition of an expanded role covering client-facing deposit businesses since 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.